SlideShare a Scribd company logo
Diseases of the autoimmune
system
Dr. Fardan Qadeer
Dept. Of Pathology
CIMS and H, Lucknow
SLE
Systemic Lupus Erythematosus
It is an autoimmune disorder which involves
multiple systems of the body
Incidence: it is a fairly common disease and the
prevalence is as high as 1 in 2500
Gender: It has a strong female predisposition,
female is to male ratio is as high as 9:1
Age: it can occur at any age group but usually
common in 2nd to 3rd decade of life
Etiology: The exact etiology of the disease is
unknown but various factors are attributed to
the development of autoimmunity
• Genetic factors:
▫ A high rate of concordance in monozygotic twins
(25%)
▫ Positive association of disease with class 2 HLA
gene particularly HLA-DQ
• Environmental factors:
▫ Ultraviolet radiation (sun exposure) exacerbates
the lesion
▫ Drugs: certain drugs like procainamide and
hydralazine may lead to development of SLE like
features
▫ Role of estrogens can be attributed to the higher
incidance of disease in females
The fundamental defect in SLE is failure to
maintain self-tolerance
• As a result of this a large number of auto
antibodies are produced which cause tissue
destruction by two mechanism
▫ Type 2 hypersensitivity: characterised by
formation of antibodies against blood components
and resulting in haematological derangement
▫ Type 3 hypersensitivity: immune complex get
deposited in different tissues resulting in systemic
resposes
Pathology: The disease is characterised by formation of
various antibodies
• Antinuclear antibodies(ANA): these are antibodies
against common nuclear antigen that include both DNA
and RNA
• Antibodies to Double stranded DNA (anti-dsDNA) and
single stranded DNA (anti-ssDNA) are most specific
• Antibodies to smith antigen(anti-SmAg) are also formed
which is a part of ribonuleoprotein
• Anti ribonuleoproteins(anti-RNP) antibodies
• Anti histone antibodies
• Anti nucleolor antibodies
• Anti phospholipid antibodies
• Renal lesions: kidney involvement is one of the
most important feature of SLE
▫ It commonly involves the glomeruli however
tubules and interstitium may be affected
▫ It is due to depostion of immune complexes in the
kidney and subsequent destruction
Extensive sub endothelial deposition of immune complexes
‘wire loop lesion’ and marked cellularity
• Small Blood vessels: Small arteries and
arterioles are involved. It is characterised by
necrosis and immune complex deposition
• Skin: There is liquifactive
degeneration of the basal layer of
the epidermis and deposition of
immune complexes at the dermo
epidermal junction
• Cardiac lesions (Libman Sacks
endocarditis) characterised by
presence of vegitations on the
mitral and tricuspid valves. It can
also cause pericarditis.
• CNS: involvement due to formation of thrombus
in the vessel walls caused by ANA deposits. It
leads to microinfarcts and subsiquent
neurological deficit.
Clinical Features
• Malar rash:
 Characterised by erythematous and maculopapular
eruptions over the malar eminance and bridge of the nose
• Discoid rash
• Photosensitivity
• Pain less oral or oropharyngeal ulcers
• Arthritis
• Serositis: Pluritis and Pericarditis
• Renal disorders: Renal failure in advanced disease is
the most important cause of death
 Persistant proteinuria >0.5 gm/dl
 Presence of cellular cast
• Neurological involvement:
 Seizures
 Psychotic Manifestations
 Focal Neurological deficit
• Hematological features
 Anemia and reticulocytosis
 Leucopenia (<4000/mm3)
 Thrombocytopenia
Laboratory Diagnosis
• LE cells: It was the first
diagnostic test for SLE. It is
based on the principal that the
ANAs cannot penetrate the
intact cells hence the cell
nucleus is exposed to bind the
ANA resulting in formation of a
homogenous mass called as LE
body
• This mass is further engulfed
by phagocytic leucocytes
(polymorphs and monocytes)
to form a LE cell
• This is positive in 70% cases of
SLE only
• Antibody titre: It is more reliable than LE cells
immunofluorescence test is positive in almost
100% cases
▫ Anti DNA antibodies
▫ Anti Smith antibodies
▫ Ant nucleolar antibodies
• Supportive evidances
▫ Proteinuria
▫ MRI brain showing microinfarct
▫ Evidance of Pleural effusion on X Ray
▫ Evidance of valvular lesions on 2D Echo

More Related Content

What's hot

Pathology of Demyelinating Disease
Pathology of Demyelinating DiseasePathology of Demyelinating Disease
Pathology of Demyelinating Disease
ML Cohen
 
Np resident lecture-wmdisease2009-slideshareupload
Np resident lecture-wmdisease2009-slideshareuploadNp resident lecture-wmdisease2009-slideshareupload
Np resident lecture-wmdisease2009-slideshareupload
charleswhite3
 
Challenges in the treatment against multiple sclerosis
Challenges in the treatment against multiple sclerosisChallenges in the treatment against multiple sclerosis
Challenges in the treatment against multiple sclerosis
Nicolas Farrands
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
Kapil Dhital
 

What's hot (20)

Systemic lupus erythematous
Systemic lupus erythematousSystemic lupus erythematous
Systemic lupus erythematous
 
Sle
SleSle
Sle
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
 
Multiple sclerosis adjusted to publish
Multiple sclerosis adjusted to publishMultiple sclerosis adjusted to publish
Multiple sclerosis adjusted to publish
 
Pathology of Demyelinating Disease
Pathology of Demyelinating DiseasePathology of Demyelinating Disease
Pathology of Demyelinating Disease
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
 
Np resident lecture-wmdisease2009-slideshareupload
Np resident lecture-wmdisease2009-slideshareuploadNp resident lecture-wmdisease2009-slideshareupload
Np resident lecture-wmdisease2009-slideshareupload
 
Genetic Insights Into Multiple Sclerosis Pathogenesis
Genetic Insights Into Multiple Sclerosis PathogenesisGenetic Insights Into Multiple Sclerosis Pathogenesis
Genetic Insights Into Multiple Sclerosis Pathogenesis
 
Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis
Multiple Sclerosis
 
Challenges in the treatment against multiple sclerosis
Challenges in the treatment against multiple sclerosisChallenges in the treatment against multiple sclerosis
Challenges in the treatment against multiple sclerosis
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
 
Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis
Multiple Sclerosis
 
1.multiple sclerosis
1.multiple sclerosis1.multiple sclerosis
1.multiple sclerosis
 
stroke and multiple sclerosis
stroke and multiple sclerosisstroke and multiple sclerosis
stroke and multiple sclerosis
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
 
nasim badarna - demyelinating disease
nasim badarna - demyelinating diseasenasim badarna - demyelinating disease
nasim badarna - demyelinating disease
 
Sle and systemic sclerosis
Sle and systemic sclerosisSle and systemic sclerosis
Sle and systemic sclerosis
 
Systemic Lupus Erythematous (SLE)
Systemic Lupus Erythematous (SLE)Systemic Lupus Erythematous (SLE)
Systemic Lupus Erythematous (SLE)
 

Similar to Systemic Lupas Eruthmatosus

dermatology.Connective tissue diseases.(dr.darseem)
dermatology.Connective tissue diseases.(dr.darseem)dermatology.Connective tissue diseases.(dr.darseem)
dermatology.Connective tissue diseases.(dr.darseem)
student
 

Similar to Systemic Lupas Eruthmatosus (20)

Systemic Lupus Erythematosus
Systemic Lupus ErythematosusSystemic Lupus Erythematosus
Systemic Lupus Erythematosus
 
Sle &amp; polyarteritis nodosa
Sle &amp; polyarteritis nodosaSle &amp; polyarteritis nodosa
Sle &amp; polyarteritis nodosa
 
Cutaneous lupus erythematosus
Cutaneous lupus erythematosusCutaneous lupus erythematosus
Cutaneous lupus erythematosus
 
Systemic lupus erythmatosus
Systemic lupus erythmatosusSystemic lupus erythmatosus
Systemic lupus erythmatosus
 
SLE and its Associated Disorders
SLE and its Associated DisordersSLE and its Associated Disorders
SLE and its Associated Disorders
 
Systemic Lupus Erythematosus .pptx
Systemic Lupus Erythematosus  .pptxSystemic Lupus Erythematosus  .pptx
Systemic Lupus Erythematosus .pptx
 
Connective tissue diseases
Connective tissue diseases Connective tissue diseases
Connective tissue diseases
 
Systemic Lupus Erythematosus -SLE PT2.ppt
Systemic  Lupus  Erythematosus -SLE PT2.pptSystemic  Lupus  Erythematosus -SLE PT2.ppt
Systemic Lupus Erythematosus -SLE PT2.ppt
 
systemic lupus erythematosus
systemic lupus erythematosussystemic lupus erythematosus
systemic lupus erythematosus
 
Lupus nephritis 2016
Lupus nephritis 2016Lupus nephritis 2016
Lupus nephritis 2016
 
Autoimmune Diseases.
Autoimmune Diseases.Autoimmune Diseases.
Autoimmune Diseases.
 
dermatology.Connective tissue diseases.(dr.darseem)
dermatology.Connective tissue diseases.(dr.darseem)dermatology.Connective tissue diseases.(dr.darseem)
dermatology.Connective tissue diseases.(dr.darseem)
 
Connective Tissue Disorders.pptx
Connective Tissue Disorders.pptxConnective Tissue Disorders.pptx
Connective Tissue Disorders.pptx
 
Diagnosis and management sle
Diagnosis  and  management sleDiagnosis  and  management sle
Diagnosis and management sle
 
Central nervous system 2
Central nervous system 2Central nervous system 2
Central nervous system 2
 
Sle diagnosis &amp; treatment
Sle diagnosis &amp; treatmentSle diagnosis &amp; treatment
Sle diagnosis &amp; treatment
 
SYSTEMIC LUPUS ERYTHEMATOSUS.pptx
SYSTEMIC LUPUS ERYTHEMATOSUS.pptxSYSTEMIC LUPUS ERYTHEMATOSUS.pptx
SYSTEMIC LUPUS ERYTHEMATOSUS.pptx
 
Lupus Nephritis :From Basics To Practice
Lupus Nephritis :From Basics To PracticeLupus Nephritis :From Basics To Practice
Lupus Nephritis :From Basics To Practice
 
Systemic lupus erythematosus
Systemic  lupus erythematosusSystemic  lupus erythematosus
Systemic lupus erythematosus
 
Mctd final
Mctd finalMctd final
Mctd final
 

More from Fardan Qadeer

Raynaud’s phenomenon
Raynaud’s phenomenonRaynaud’s phenomenon
Raynaud’s phenomenon
Fardan Qadeer
 

More from Fardan Qadeer (15)

Emesis and anti emetic drugs
Emesis and anti emetic drugsEmesis and anti emetic drugs
Emesis and anti emetic drugs
 
Anti coagulants & fibrinolytics
Anti coagulants & fibrinolyticsAnti coagulants & fibrinolytics
Anti coagulants & fibrinolytics
 
Dopamine
DopamineDopamine
Dopamine
 
G protein coupled receptor
G protein coupled receptorG protein coupled receptor
G protein coupled receptor
 
Schedule Y
Schedule YSchedule Y
Schedule Y
 
Obesity
ObesityObesity
Obesity
 
Good clinical practices(GCP)
Good clinical practices(GCP)Good clinical practices(GCP)
Good clinical practices(GCP)
 
Masticating apparatus
Masticating apparatusMasticating apparatus
Masticating apparatus
 
Raynaud’s phenomenon
Raynaud’s phenomenonRaynaud’s phenomenon
Raynaud’s phenomenon
 
Anatomy of maxilla and mandible
Anatomy of maxilla and mandibleAnatomy of maxilla and mandible
Anatomy of maxilla and mandible
 
Autoimmunity
AutoimmunityAutoimmunity
Autoimmunity
 
What is islam
What is islamWhat is islam
What is islam
 
Instruments
InstrumentsInstruments
Instruments
 
Instruments
InstrumentsInstruments
Instruments
 
People of the world
People of the worldPeople of the world
People of the world
 

Recently uploaded

Recently uploaded (20)

IOS-PENTESTING-BEGINNERS-PRACTICAL-GUIDE-.pptx
IOS-PENTESTING-BEGINNERS-PRACTICAL-GUIDE-.pptxIOS-PENTESTING-BEGINNERS-PRACTICAL-GUIDE-.pptx
IOS-PENTESTING-BEGINNERS-PRACTICAL-GUIDE-.pptx
 
IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024
 
UiPath Test Automation using UiPath Test Suite series, part 1
UiPath Test Automation using UiPath Test Suite series, part 1UiPath Test Automation using UiPath Test Suite series, part 1
UiPath Test Automation using UiPath Test Suite series, part 1
 
Where to Learn More About FDO _ Richard at FIDO Alliance.pdf
Where to Learn More About FDO _ Richard at FIDO Alliance.pdfWhere to Learn More About FDO _ Richard at FIDO Alliance.pdf
Where to Learn More About FDO _ Richard at FIDO Alliance.pdf
 
Intro in Product Management - Коротко про професію продакт менеджера
Intro in Product Management - Коротко про професію продакт менеджераIntro in Product Management - Коротко про професію продакт менеджера
Intro in Product Management - Коротко про професію продакт менеджера
 
Extensible Python: Robustness through Addition - PyCon 2024
Extensible Python: Robustness through Addition - PyCon 2024Extensible Python: Robustness through Addition - PyCon 2024
Extensible Python: Robustness through Addition - PyCon 2024
 
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
 
Agentic RAG What it is its types applications and implementation.pdf
Agentic RAG What it is its types applications and implementation.pdfAgentic RAG What it is its types applications and implementation.pdf
Agentic RAG What it is its types applications and implementation.pdf
 
How Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdf
How Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdfHow Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdf
How Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdf
 
Syngulon - Selection technology May 2024.pdf
Syngulon - Selection technology May 2024.pdfSyngulon - Selection technology May 2024.pdf
Syngulon - Selection technology May 2024.pdf
 
Buy Epson EcoTank L3210 Colour Printer Online.pdf
Buy Epson EcoTank L3210 Colour Printer Online.pdfBuy Epson EcoTank L3210 Colour Printer Online.pdf
Buy Epson EcoTank L3210 Colour Printer Online.pdf
 
Speed Wins: From Kafka to APIs in Minutes
Speed Wins: From Kafka to APIs in MinutesSpeed Wins: From Kafka to APIs in Minutes
Speed Wins: From Kafka to APIs in Minutes
 
Salesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
Salesforce Adoption – Metrics, Methods, and Motivation, Antone KomSalesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
Salesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
 
Top 10 Symfony Development Companies 2024
Top 10 Symfony Development Companies 2024Top 10 Symfony Development Companies 2024
Top 10 Symfony Development Companies 2024
 
Enterprise Knowledge Graphs - Data Summit 2024
Enterprise Knowledge Graphs - Data Summit 2024Enterprise Knowledge Graphs - Data Summit 2024
Enterprise Knowledge Graphs - Data Summit 2024
 
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
 
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptxUnpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
 
FDO for Camera, Sensor and Networking Device – Commercial Solutions from VinC...
FDO for Camera, Sensor and Networking Device – Commercial Solutions from VinC...FDO for Camera, Sensor and Networking Device – Commercial Solutions from VinC...
FDO for Camera, Sensor and Networking Device – Commercial Solutions from VinC...
 
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya HalderCustom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
 
ECS 2024 Teams Premium - Pretty Secure
ECS 2024   Teams Premium - Pretty SecureECS 2024   Teams Premium - Pretty Secure
ECS 2024 Teams Premium - Pretty Secure
 

Systemic Lupas Eruthmatosus

  • 1. Diseases of the autoimmune system Dr. Fardan Qadeer Dept. Of Pathology CIMS and H, Lucknow
  • 2. SLE Systemic Lupus Erythematosus It is an autoimmune disorder which involves multiple systems of the body Incidence: it is a fairly common disease and the prevalence is as high as 1 in 2500 Gender: It has a strong female predisposition, female is to male ratio is as high as 9:1 Age: it can occur at any age group but usually common in 2nd to 3rd decade of life
  • 3. Etiology: The exact etiology of the disease is unknown but various factors are attributed to the development of autoimmunity • Genetic factors: ▫ A high rate of concordance in monozygotic twins (25%) ▫ Positive association of disease with class 2 HLA gene particularly HLA-DQ
  • 4. • Environmental factors: ▫ Ultraviolet radiation (sun exposure) exacerbates the lesion ▫ Drugs: certain drugs like procainamide and hydralazine may lead to development of SLE like features ▫ Role of estrogens can be attributed to the higher incidance of disease in females
  • 5.
  • 6. The fundamental defect in SLE is failure to maintain self-tolerance • As a result of this a large number of auto antibodies are produced which cause tissue destruction by two mechanism ▫ Type 2 hypersensitivity: characterised by formation of antibodies against blood components and resulting in haematological derangement ▫ Type 3 hypersensitivity: immune complex get deposited in different tissues resulting in systemic resposes
  • 7. Pathology: The disease is characterised by formation of various antibodies • Antinuclear antibodies(ANA): these are antibodies against common nuclear antigen that include both DNA and RNA • Antibodies to Double stranded DNA (anti-dsDNA) and single stranded DNA (anti-ssDNA) are most specific • Antibodies to smith antigen(anti-SmAg) are also formed which is a part of ribonuleoprotein • Anti ribonuleoproteins(anti-RNP) antibodies • Anti histone antibodies • Anti nucleolor antibodies • Anti phospholipid antibodies
  • 8. • Renal lesions: kidney involvement is one of the most important feature of SLE ▫ It commonly involves the glomeruli however tubules and interstitium may be affected ▫ It is due to depostion of immune complexes in the kidney and subsequent destruction
  • 9. Extensive sub endothelial deposition of immune complexes ‘wire loop lesion’ and marked cellularity
  • 10. • Small Blood vessels: Small arteries and arterioles are involved. It is characterised by necrosis and immune complex deposition
  • 11. • Skin: There is liquifactive degeneration of the basal layer of the epidermis and deposition of immune complexes at the dermo epidermal junction • Cardiac lesions (Libman Sacks endocarditis) characterised by presence of vegitations on the mitral and tricuspid valves. It can also cause pericarditis.
  • 12. • CNS: involvement due to formation of thrombus in the vessel walls caused by ANA deposits. It leads to microinfarcts and subsiquent neurological deficit.
  • 13. Clinical Features • Malar rash:  Characterised by erythematous and maculopapular eruptions over the malar eminance and bridge of the nose • Discoid rash • Photosensitivity • Pain less oral or oropharyngeal ulcers • Arthritis • Serositis: Pluritis and Pericarditis • Renal disorders: Renal failure in advanced disease is the most important cause of death  Persistant proteinuria >0.5 gm/dl  Presence of cellular cast
  • 14. • Neurological involvement:  Seizures  Psychotic Manifestations  Focal Neurological deficit • Hematological features  Anemia and reticulocytosis  Leucopenia (<4000/mm3)  Thrombocytopenia
  • 15.
  • 16. Laboratory Diagnosis • LE cells: It was the first diagnostic test for SLE. It is based on the principal that the ANAs cannot penetrate the intact cells hence the cell nucleus is exposed to bind the ANA resulting in formation of a homogenous mass called as LE body • This mass is further engulfed by phagocytic leucocytes (polymorphs and monocytes) to form a LE cell • This is positive in 70% cases of SLE only
  • 17. • Antibody titre: It is more reliable than LE cells immunofluorescence test is positive in almost 100% cases ▫ Anti DNA antibodies ▫ Anti Smith antibodies ▫ Ant nucleolar antibodies • Supportive evidances ▫ Proteinuria ▫ MRI brain showing microinfarct ▫ Evidance of Pleural effusion on X Ray ▫ Evidance of valvular lesions on 2D Echo